Protectivity and Antibody Response of Seven Avian Reovirus Live Vaccines in SPF Chickens

家禽里奧活毒疫苗在SPF雞之保護力和抗體反應

林茂勇(Maw-Yeong Lin) ； 蔡明成(Ming-Cheng Tsai) ； 劉宏仁(Hung-Jen Liu) ； 郭良嘉(Liang-Chia Kuo) ； 陳貞華(Jen-Hwa Chen)

《臺灣獸醫學雜誌》 30卷4期 (2004/12) Pp. 256-262

https://doi.org/10.7009/TVJ.200412.0256

摘要

Live avian reovirus (ARV) vaccine has long been using in poultry industry. Safety, protectivity and antibody response of each individual vaccine is still not clear. Seven commercial live ARV vaccines were each administrated subcutanously twice to 7 groups of 20 SPF chickens at 1 and 5 weeks of age. A control group was also included in this experiment. Blood from all chickens were collected at 3 and 7 weeks of age for ARV enzyme-linked immunosorbent assay (ELISA) antibody test. At 9-week-old, 10 birds per group were challenged via the footpad with the 1733 and 2408 strains of ARV. The increase in the footpad thickness and swelling at 7 and 14 days post challenge (DPC) were calculated. AII vaccinated birds were survived in good health. At 3 and 7 weeks of age, 1 (14.2%) and 6 (85.5%) vaccinated groups of chickens had geometric mean ELlSA titers (GMT) in excess of 1:1000 respectively. At 7 and 14 DPC, 2 and 1 vaccinated group had the increase of footpad swelling in millimeter significantly (P＜0.05) less than the control group. AII the vaccinated groups had footpad swellings and leg hemorrhage scores significantly (P＜0.05) less than the control group. Commercial live ARV vaccines provide some protectivity against virulent ARV challenge, but the protectivity is the remaining virulence of vaccine virus corelated.

關鍵字

家禽里奧病毒（ARV） ； 活毒疫苗

並列摘要

Live avian reovirus (ARV) vaccine has long been using in poultry industry. Safety, protectivity and antibody response of each individual vaccine is still not clear. Seven commercial live ARV vaccines were each administrated subcutanously twice to 7 groups of 20 SPF chickens at 1 and 5 weeks of age. A control group was also included in this experiment. Blood from all chickens were collected at 3 and 7 weeks of age for ARV enzyme-linked immunosorbent assay (ELISA) antibody test. At 9-week-old, 10 birds per group were challenged via the footpad with the 1733 and 2408 strains of ARV. The increase in the footpad thickness and swelling at 7 and 14 days post challenge (DPC) were calculated. AII vaccinated birds were survived in good health. At 3 and 7 weeks of age, 1 (14.2%) and 6 (85.5%) vaccinated groups of chickens had geometric mean ELlSA titers (GMT) in excess of 1:1000 respectively. At 7 and 14 DPC, 2 and 1 vaccinated group had the increase of footpad swelling in millimeter significantly (P＜0.05) less than the control group. AII the vaccinated groups had footpad swellings and leg hemorrhage scores significantly (P＜0.05) less than the control group. Commercial live ARV vaccines provide some protectivity against virulent ARV challenge, but the protectivity is the remaining virulence of vaccine virus corelated.

並列關鍵字

avian reovirus (ARV) ； live vaccine